John Moroney to Disease-Free Survival
This is a "connection" page, showing publications John Moroney has written about Disease-Free Survival.
Connection Strength
0.084
-
Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity. Clin Cancer Res. 2012 Oct 15; 18(20):5796-805.
Score: 0.084